Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine

M Nassan, WT Nicholson, MA Elliott, CRR Vitek… - Mayo Clinic …, 2016 - Elsevier
Antidepressants are commonly prescribed medications in the United States, and there is
increasing interest in individualizing treatment selection for more than 20 US Food and Drug …

Development of human membrane transporters: drug disposition and pharmacogenetics

MG Mooij, AT Nies, CAJ Knibbe, E Schaeffeler… - Clinical …, 2016 - Springer
Membrane transporters play an essential role in the transport of endogenous and
exogenous compounds, and consequently they mediate the uptake, distribution, and …

Characterization of the microDNA through the response to chemotherapeutics in lymphoblastoid cell lines

P Mehanna, V Gagné, M Lajoie, JF Spinella… - PloS one, 2017 - journals.plos.org
Recently, a new class of extrachromosomal circular DNA, called microDNA, was identified.
They are on average 100 to 400 bp long and are derived from unique non-repetitive …

Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment

N Kotur, J Lazic, B Ristivojevic, B Stankovic, V Gasic… - Genes, 2020 - mdpi.com
Methotrexate (MTX) is one of the staples of pediatric acute lymphoblastic leukemia (ALL)
treatment. MTX targets the folate metabolic pathway (FMP). Abnormal function of the …

Association of microRNA polymorphisms with toxicities induced by methotrexate in children with acute lymphoblastic leukemia

V Karpa, K Kalinderi, L Fidani, A Tragiannidis - Hematology Reports, 2023 - mdpi.com
Methotrexate (MTX), a structurally related substance to folic acid, is an important
chemotherapeutic agent used for decades in the treatment of pediatric acute lymphoblastic …

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

M Umerez, A Gutierrez-Camino… - Pharmacogenomics …, 2017 - Taylor & Francis
Methotrexate (MTX) is an important component in the therapy used to treat childhood acute
lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key …

Pharmacogenetics of anti-cancer drugs: state of the art and implementation–recommendations of the French National Network of Pharmacogenetics

S Quaranta, F Thomas - Therapies, 2017 - Elsevier
Individualized treatment is of special importance in oncology because the drugs used for
chemotherapy have a very narrow therapeutic index. Pharmacogenetics may contribute …

Implementation of pharmacogenetics to individualize treatment regimens for children with acute lymphoblastic leukemia

D Maamari, H El-Khoury, O Saifi… - Pharmacogenomics …, 2020 - Taylor & Francis
Despite major advances in the management and high cure rates of childhood acute
lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities …

Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia

Á Gutierrez-Camino, M Umerez… - The …, 2018 - nature.com
Vincristine (VCR), an important component of childhood acute lymphoblastic leukemia (ALL)
therapy, can cause sensory and motor neurotoxicity. This neurotoxicity could lead to dose …

Pharmacogenomics in pediatric oncology: mitigating adverse drug reactions while preserving efficacy

AA Elzagallaai, BC Carleton… - Annual review of …, 2021 - annualreviews.org
Cancer is the leading cause of death in American children older than 1 year of age. Major
developments in drugs such as thiopurines and optimization in clinical trial protocols for …